[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369341-105":59,"doc-detail-369341-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","frequency-and-outcomes-of-braf-alterations-identified-by-liquid-biopsy-in-metastatic-non-colorectal-gastrointestinal-cancers","Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers","","Study evaluates how often BRAF genomic alterations, including BRAFV600E, occur in metastatic non-colorectal gastrointestinal cancers and what they mean for real-world survival. Patients with pancreatic, gastric/gastroesophageal, hepatocellular carcinoma, or cholangiocarcinoma with cell-free DNA detected on Guardant360 between 2020 and 2023 were analyzed, with BRAF alterations grouped by class I/II/III. Overall survival was assessed in a subset using GuardantINFORM. Results report prevalence, cancer-type differences, co-occurrence patterns, and treatment frequency for BRAF inhibitors.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/frequency-and-outcomes-of-braf-alterations-identified-by-liquid-biopsy-in-metastatic-non-colorectal-gastrointestinal-cancers/369341/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/frequency-and-outcomes-of-braf-alterations-identified-by-liquid-biopsy-in-metastatic-non-colorectal-gastrointestinal-cancers/369341.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What cancers and patient timeline were included in the analysis?","Question",{"text":112,"@type":113},"The study queried patients with PDAC, GEA, HCC, or CCA with cell-free DNA detected on Guardant360 from 2020 to 2023.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were BRAF alterations classified and compared across cancer types?",{"text":117,"@type":113},"BRAF genomic alterations were grouped by class (Class I/II/III), and differences between cancer types were assessed using a chi-squared test.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings on BRAF alteration frequency and BRAFV600E prevalence?",{"text":121,"@type":113},"Across 32,480 patients, BRAF alterations were identified in 4.4%, with 19% of those being BRAFV600E, reported as 0.81% prevalence overall.",{"name":123,"@type":110,"acceptedAnswer":124},"How did BRAF alteration class relate to overall survival in this study?",{"text":125,"@type":113},"No significant differences in real-world overall survival were observed by alteration class or cancer type, although numeric differences appeared by class.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369341,1790334042,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers  \nAmit Mahipal*, 1,2,, Leslie Bucheit3, Nicole Zhang3, Reagan M. Barnett3, Michael H. Storandt2, Sakti Chakrabarti1  \n1University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States, 2Mayo Clinic, Rochester, MN, United States,  \n3Guardant Health Inc, Palo Alto, CA, United States  \n* Corresponding author: Amit Mahipal, MD, MPH, Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA ([amit.mahipal@uhhospitals.org](amit.mahipal@uhhospitals.org)) .  \nPrior Presentation: Presented in part at the 2023 ASCO Gastrointestinal Cancers Symposium.  \nAbstract  \nBackground: Impact of BRAFV600E mutations (BRAFV600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA) . Due to tumor-agnostic approvals for patients with BRAFV600E, understanding the frequency and impact of BRAF alterations across nonCRC GI cancers is essential for clinical decision-making.  \nMethods: Patients with PDAC, GEA, HCC, or CCA who had cell-free DNA detected on Guardant360 (Guardant Health) from 2020 to 2023 were queried. Prevalence of characterized BRAF genomic alterations (GA) was calculated; GAs were grouped by class (Class I/II/III) . The Chi-squared test assessed differences between cancer types. A subset of patients had outcomes analysis using GuardantINFORM, a real-world clinicogenomic database, to derive real-world overall survival (rwOS) .  \nResults: Of 32 480 included patients, BRAF GAs were identified in 4.4%; 19% were BRAFV600E (0 .81% prevalence overall) . CCA had the highest rate of BRAF GAs and BRAFV600E ( P \u003C .01); HCC and GEA had the highest rates of BRAF class II/III alterations. There were no significant differences in rwOS by alteration class or cancer type; numeric differences were observed by alteration class. Few patients were treated with BRAF inhibitors (2 .2%) . Prevalence of co-occurring alterations was unique by cancer type.  \nConclusions: Frequency of BRAF GAs, including BRAFV600E, in non-CRC GI cancers detected by liquid biopsy is similar to tissue-based rates and can be reliably used to assess BRAF status. BRAF GAs have mixed prognostic implications on survival for patients with non-CRC GI malignancies that warrant further exploration.  \nKey words: cholangiocarcinoma; pancreatic cancer; gastric cancer; BRAF; cell-free DNA.  \nImplications for practice  \nNovel drug therapeutics targeting BRAF alterations are under development. However, the frequency and types of BRAF alteration in noncolorectal gastrointestinal cancers are not well defined. In this study, using liquid biopsy, we found that the highest frequency of class 1 BRAF alterations is present in cholangiocarcinoma while Class II/III BRAF alterations are more common in hepatocellular cancer and gastroesophageal cancer. We did not observe the detrimental effect of BRAF mutations on overall survival in these tumor types. Despite the tumor-agnostic FDA approval of BRAF inhibitors, their utilization was low in clinical practice in non-colorectal gastrointestinal cancers.  \nBackground  \nBRAF is a protein kinase that functions in cell signaling pathways impacting cellular growth and differentiation and BRAF mutations have been implicated in oncogenic pathways.1 BRAF mutations have been found to have a prognostic impact and may guide therapeutic decisions in patients with multiple solid malignancies, including colorectal cancer (CRC),2-4 melanoma,5,6 and non-small cell lung cancer (NSCLC) .7 BRAFV600E is the most frequently observed and  \nbest-studied mutation, however, new studies have evaluated BRAF non-V600E mutations as well, identifying distinct phenotypic and prognostic implications of these less","cbCaihdAh7UrTGQe","https://ap.wps.com/l/cbCaihdAh7UrTGQe","pdf",559725,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Implications for practice\n## Background","[{\"question\":\"What cancers and patient timeline were included in the analysis?\",\"answer\":\"The study queried patients with PDAC, GEA, HCC, or CCA with cell-free DNA detected on Guardant360 from 2020 to 2023.\"},{\"question\":\"How were BRAF alterations classified and compared across cancer types?\",\"answer\":\"BRAF genomic alterations were grouped by class (Class I/II/III), and differences between cancer types were assessed using a chi-squared test.\"},{\"question\":\"What were the main findings on BRAF alteration frequency and BRAFV600E prevalence?\",\"answer\":\"Across 32,480 patients, BRAF alterations were identified in 4.4%, with 19% of those being BRAFV600E, reported as 0.81% prevalence overall.\"},{\"question\":\"How did BRAF alteration class relate to overall survival in this study?\",\"answer\":\"No significant differences in real-world overall survival were observed by alteration class or cancer type, although numeric differences appeared by class.\"}]","Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers | PDF",1790182135,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9afa598d6672d78b5930147ee44cbb10.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20482ec02dcf805928106523c059142c.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0aaa1f26c7b7fffe2520f6a668f0484.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6262bab3923ce331d9676f89c52b0ecb.webp",980,1287]